Research Projects

At Redoxis, research and innovation are at the heart of our work. In addition to our contract research services, we actively engage in internal and collaborative research projects aimed at advancing the understanding of autoimmune and inflammatory diseases and improving therapeutic strategies.

Internal Research Initiatives

Redoxis continuously develops and refines in vitro and in vivo models to enhance the predictability and translational relevance of preclinical studies. Our research focuses on:

  • Identifying novel biomarkers and disease mechanisms in autoimmune conditions.
  • Expanding our model portfolio as well as improving and optimizing preclinical models for inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE).
  • Developing and optimizing assay systems to improve the characterization of immune responses and therapeutic effects.

Collaborative Research Projects

Redoxis collaborates with academic institutions, biotech companies, and pharmaceutical partners to push the boundaries of immunological research. Through these collaborations, we contribute to:

  • Development of next-generation therapeutics targeting immune pathways.
  • Validation of novel drug candidates using our advanced preclinical models.
  • Exploration of new treatment strategies for rare and complex autoimmune diseases.

Commitment to Scientific Advancement

Our research efforts are driven by a commitment to scientific excellence and innovation. By staying at the forefront of immunology and inflammation research, we aim to contribute valuable insights to the scientific community and support the development of new and effective therapies.

For partnership opportunities or more information about our research projects, please contact us.

Ongoing research projects

Örebro University has been awarded SEK 12 million from the Knowledge Foundation (KK-stiftelsen) within the framework of the Synergi24 call to support research exploring the link between diet, the microbiome, and chronic diseases.

The interdisciplinary project, “The Role of the Dietary Metabolite TMAO in Chronic Diseases,” aims to investigate how the diet-related metabolite TMAO (trimethylamine N-oxide) contributes to the onset and progression of three major chronic conditions:

  • Cardiovascular disease

  • Chronic kidney disease

  • Periodontitis

TMAO is a molecule produced during the breakdown of dietary components, particularly from animal-based products such as red meat. Previous studies suggest that elevated TMAO levels are associated with the development of atherosclerosis and chronic kidney disease.

Running from 2025 to 2030, the project brings together a distinguished consortium including:

  • Clinical experts from Region Örebro län, Karolinska Institutet, and Karolinska Universitetssjukhuset

  • Industrial partners including Bio-Rad Laboratories, QIAGEN, Redoxis AB, and Probi AB

  • International collaborators from University of Lincoln, University of Glasgow, and Temple University

The project is co-financed by industry partners with an additional SEK 12 million and is anchored at the Centre for Food and Health at Örebro University.